Handläggning av samhälls-förvärvad pneumoni hos vuxna: Evidensbaserade riktlinjer från Svenska infektionsläkarfö reningen

Lakartidningen

Volumn 105, Issue 38, 2008, Pages 2582-2587

  Strålin, Kristoffer ^a   Goscinski, Gunilla ^b   Hedlund, Jonas ^c   Lidman, Christer ^c   Spindler, Carl ^c   Örtqvist, Åke ^d   Holmberg, Hans ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PENICILLIN G; PENICILLIN V;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; INCIDENCE; LOBAR PNEUMONIA; MEDICAL SOCIETY; MICROBIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; SWEDEN;

ADULT; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HOSPITALIZATION; HUMANS; INCIDENCE; PENICILLIN G; PENICILLIN V; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; SWEDEN;

EID: 53549112168     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275(2):134-41.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72.
3. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax. 2001;56 Suppl 4:IV1-64.
4. Hedlund J, Strålin K, Örtqvist Å, Holmberg H; Community-Acquired Pneumonia Working Group of the Swedish Society of Infectious Diseases. Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults. Scand J Infect Dis. 2005;37:791-805.
5. Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol. 1993;137(9):977-88.
6. Hedlund J, Örtqvist A, Ahlqvist T, Augustinsson A, Beckman H, Blanck C, et al. Management of patients with community-acquired pneumonia treated in hospital in Sweden. Scand J Infect Dis. 2002;34(12):887-92.
7. Lidman C, Burman LG, Lagergren A, Örtqvist Å. Limited value of routine microbiological diagnostics in patients hospitalized for community-acquired pneumonia. Scand J Infect Dis. 2002;34(12):873-9.
8. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-82.
9. Strålin K. Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia. Int J Antimicrob Agents. 2008;31:3-11.
10. Blazquez RM, Espinosa FJ, Martinez-Toldos CM, Alemany L, Garcia-Orenes MC, Segovia M. Sensitivity of urinary antigen test in relation to clinical severity in a large outbreak of Legionella pneumonia in Spain. Eur J Clin Microbiol Infect Dis. 2005;24(7):488-91.
11. Olsson-Liljequist B, Henriques Normark B, Struwe J, Söderblom T. Streptococcus pneumoniae: Annual Resistance Surveillance and Quality Control (RSQC) programme. In: Cars O, Olsson-Liljequist B, editors. Swedres 2006, a report on Swedish antibiotic utilisation and resistance in human medicine. Solna: Smittskyddsinstitutet; 2006. p. 22-3.
12. Paterson DL. »Collateral damage« from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38 Suppl 4:S341-5.
13. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med. 2005;165(17):1992-2000.
14. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002;162(11):1278-84.
15. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004;164(5):502-8.
16. Holmberg H, Kragsbjerg P. Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow-up. Scand J Infect Dis. 1993;25(1):93-100.
17. Menendez R, Perpina M, Torres A. Evaluation of nonresolving and progressive pneumonia. Semin Respir Infect. 2003;18(2):103-11.
18. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2001;(4):CD001269.
19. Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2003(4):CD000422.
20. Örtqvist A, Hedlund J, Burman LÅ, Elbel E, Hofer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998;351(9100):399-403.